{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:52:40Z","timestamp":1793659960336,"version":"4.5.1"},"reference-count":41,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["DP190027"],"award-info":[{"award-number":["DP190027"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,11,16]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite significant progress in cancer immunotherapy in recent years, resistance to existing immune checkpoint therapies (ICT) is common. V-domain Ig suppressor of T cell activation (VISTA), a predominantly myeloid immune checkpoint regulator, represents a promising therapeutic target due to its role in suppressing proinflammatory antitumor responses in myeloid-enriched tumor microenvironments. However, uncertainty around the cognate VISTA ligand has made the development of effective anti-VISTA antibodies challenging. The expression of VISTA on normal immune cell subtypes argues for a neutralizing non-depleting antibody, however, previous reported anti-VISTA antibodies use IgG1 Fc isotypes that deplete VISTA+ cells by antibody dependent cellular cytotoxicity\/complement dependent cytotoxicity and these antibodies have shown fast serum clearance and immune toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Here we used a rational antibody discovery approach to develop the first Fc-independent anti-VISTA antibody, HMBD-002, that binds a computationally predicted functional epitope within the C-C-loop, distinct from other known anti-VISTA antibodies. This epitope is species-conserved allowing robust in vitro and in vivo testing of HMBD-002 in human and murine models of immune activation and cancer including humanized mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrate here that blockade by HMBD-002 inhibits VISTA binding to potential partners, including V-Set and Immunoglobulin domain containing 3, to reduce myeloid-derived suppression of T cell activity and prevent neutrophil migration. Analysis of immune cell milieu suggests that HMBD-002 treatment stimulates a proinflammatory phenotype characterized by a Th1\/Th17 response, recapitulating a phenotype previously noted in VISTA knockout models. This mechanism of action is further supported by immune-competent syngenic and humanized mouse models of colorectal, breast and lung cancer where neutralizing VISTA, without depleting VISTA expressing cells, significantly inhibited tumor growth while decreasing infiltration of suppressive myeloid cells and increasing T cell activity. Finally, we did not observe either the fast serum clearance or immune toxicities that have been reported for IgG1 antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, we have shown that VISTA-induced immune suppression can be reversed by blockade of the functional C-C\u2019 loop region of VISTA with a first-in-class rationally targeted and non-depleting IgG4 isotype anti-VISTA antibody, HMBD-002. This antibody represents a highly promising novel therapy in the VISTA-suppressed ICT non-responder population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-003382","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T11:46:38Z","timestamp":1644234398000},"page":"e003382","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":67,"title":["Rationally targeted anti-VISTA antibody that blockades the C-C\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04475523","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dipti","family":"Thakkar","sequence":"first","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Paliwal","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Dharmadhikari","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Guan","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Liu","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Kar","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil K","family":"Tulsian","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and Department of Biochemistry, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J","family":"Gruber","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"DiMascio","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad H","family":"Paszkiewicz","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers J","family":"Ingram","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-2619","authenticated-orcid":false,"given":"Jerome","family":"D Boyd-Kirkup","sequence":"additional","affiliation":[{"name":"Hummingbird Bioscience, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"2025100306023617000_10.2.e003382.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025100306023617000_10.2.e003382.2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619"},{"key":"2025100306023617000_10.2.e003382.3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1504"},{"key":"2025100306023617000_10.2.e003382.4","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13415"},{"key":"2025100306023617000_10.2.e003382.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2020.02.002","article-title":"The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers","volume":"52","author":"Wang","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025100306023617000_10.2.e003382.6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1506"},{"key":"2025100306023617000_10.2.e003382.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0524"},{"key":"2025100306023617000_10.2.e003382.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01411-1"},{"key":"2025100306023617000_10.2.e003382.9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax1159"},{"key":"2025100306023617000_10.2.e003382.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420370112"},{"key":"2025100306023617000_10.2.e003382.11","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13001"},{"key":"2025100306023617000_10.2.e003382.12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4308"},{"key":"2025100306023617000_10.2.e003382.13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1811067116","article-title":"Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer","volume":"116","author":"Blando","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100306023617000_10.2.e003382.14","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod Pathol"},{"key":"2025100306023617000_10.2.e003382.15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100306023617000_10.2.e003382.16","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep"},{"key":"2025100306023617000_10.2.e003382.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1261669"},{"key":"2025100306023617000_10.2.e003382.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1674-5"},{"key":"2025100306023617000_10.2.e003382.19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41590-019-0563-2","article-title":"Acidity changes immunology: a new VISTA pathway","volume":"21","author":"Mahoney","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100306023617000_10.2.e003382.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00190.x"},{"key":"2025100306023617000_10.2.e003382.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2025100306023617000_10.2.e003382.22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0515"},{"key":"2025100306023617000_10.2.e003382.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.031"},{"key":"2025100306023617000_10.2.e003382.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313-5"},{"key":"2025100306023617000_10.2.e003382.25","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2011.367"},{"key":"2025100306023617000_10.2.e003382.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71519-4","article-title":"An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA","volume":"10","author":"Mehta","year":"2020","journal-title":"Sci Rep"},{"key":"2025100306023617000_10.2.e003382.27","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-89"},{"key":"2025100306023617000_10.2.e003382.28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3390\/vaccines1040527","article-title":"Dendritic cell-induced Th1 and Th17 cell differentiation for cancer therapy","volume":"1","author":"Terhune","year":"2013","journal-title":"Vaccines"},{"key":"2025100306023617000_10.2.e003382.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02641","article-title":"Defining the signature of vista on myeloid cell chemokine responsiveness","volume":"10","author":"Broughton","year":"2019","journal-title":"Front Immunol"},{"key":"2025100306023617000_10.2.e003382.30","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines4030031","article-title":"Neutrophils and granulocytic MDSC: the Janus God of cancer immunotherapy","volume":"4","author":"Zilio","year":"2016","journal-title":"Vaccines"},{"key":"2025100306023617000_10.2.e003382.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02719.x"},{"key":"2025100306023617000_10.2.e003382.32","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7"},{"key":"2025100306023617000_10.2.e003382.33","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0518-z"},{"key":"2025100306023617000_10.2.e003382.34","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1376"},{"key":"2025100306023617000_10.2.e003382.35","doi-asserted-by":"crossref","unstructured":"Mostb\u00f6ck S , Wu H , Fenn T . Abstract 3266: distinct immune stimulatory functions of anti-human VISTA antibodies are determined by the antibody isotype. Immunology 2019:3266.","DOI":"10.1158\/1538-7445.AM2019-3266"},{"key":"2025100306023617000_10.2.e003382.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02554-3"},{"key":"2025100306023617000_10.2.e003382.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2542"},{"key":"2025100306023617000_10.2.e003382.38","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0020"},{"key":"2025100306023617000_10.2.e003382.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099226"},{"key":"2025100306023617000_10.2.e003382.40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909"},{"key":"2025100306023617000_10.2.e003382.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01638","article-title":"Decreased expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA","volume":"10","author":"Hid Cadena","year":"2019","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1136\/jitc-2021-003382corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:02:46Z","timestamp":1759496566000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,7]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/jitc-2021-003382"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003382","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}